Difference between revisions of "Deng J, et al. BMC Cancer (2019) cited as Ref 367 in DOI: 10.1038/s41392-020-0110-5 (Q9630)"
Jump to navigation
Jump to search
(Created claim: Publication Date (P100): 2019, #quickstatements; #temporary_batch_1590002823654) |
(Created claim: Page(s) (P105): 618-, #quickstatements; #temporary_batch_1590074839150) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Property / Published In Name String | |||
| + | BMC Cancer | ||
| Property / Published In Name String: BMC Cancer / rank | |||
| + | Normal rank | ||
| Property / Volume | |||
| + | 19 | ||
| Property / Volume: 19 / rank | |||
| + | Normal rank | ||
| Property / title | |||
| + | Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression (English) | ||
| Property / title: Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 618- | ||
| Property / Page(s): 618- / rank | |||
| + | Normal rank | ||
Latest revision as of 15:39, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Deng J, et al. BMC Cancer (2019) cited as Ref 367 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Deng J
0 references
2019
0 references
BMC Cancer
0 references
19
0 references
Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression (English)
0 references
618-
0 references
